Get the Stockscreener App
2.58
2.79%
0.07
Nuvation Bio Inc stock is traded at $2.58, with a volume of 2.06M.
It is up +2.79% in the last 24 hours and down -3.73% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
See More
Previous Close:
$2.51
Open:
$2.55
24h Volume:
2.06M
Relative Volume:
0.90
Market Cap:
$868.34M
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-7.3714
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-0.39%
1M Performance:
-3.73%
6M Performance:
-14.00%
1Y Performance:
+76.71%
1-Day Range:
$2.50
$2.66
1-Week Range:
$2.47
$2.765
52-Week Range:
$1.44
$4.1598
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.58 | 868.34M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat
Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat
HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World
FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada
Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat
FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia
Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
Innovent wins second China nod for Nuvation-partnered cancer therapy - MSN
Nuvation Bio (NYSE:NUVB) Trading Up 10%Time to Buy? - MarketBeat
Innovent wins China nod for Nuvation Bio drug (NUVB:NYSE) - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Geode Capital Management LLC Boosts Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.7% last week but have benefitted from longer-term gains - Simply Wall St
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? - Insider Monkey
FDA Accepts for Priority Review Nuvation Bio’s NDA for Taletrectinib to Treat Advanced ROS1-positive Non-Small Cell Lung Cancer - Specialty Pharmacy Continuum
Nuvation Bio Inc. (NYSE:NUVB) Stock Position Raised by State Street Corp - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Stake Increased by State Street Corp - MarketBeat
FDA sets review date for Nuvation Bio’s cancer drug By Investing.com - Investing.com Nigeria
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio Inc.'s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com
Nuvation Bio’s (NUVB) Outperform Rating Reaffirmed at Wedbush - Defense World
Wedbush Reaffirms "Outperform" Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
FDA sets review date for Nuvation Bio's cancer drug By Investing.com - Investing.com Australia
FDA priority review for Nuvation Bio's taletrectinib - The Pharma Letter
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
FDA sets review date for Nuvation Bio's cancer drug - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,670 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Wellington Management Group LLP Purchases 283,642 Shares of Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Up 5%Still a Buy? - MarketBeat
Verition Fund Management LLC Sells 13,409 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: taletrectinib drives stock outlook amid pipeline shifts - Investing.com
Clear Street sets Nuvation Bio at Buy with $5 target By Investing.com - Investing.com South Africa
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):